NASH
MCID: NNL004
MIFTS: 56

Nonalcoholic Fatty Liver Disease (NASH)

Categories: Cancer diseases, Liver diseases, Metabolic diseases

Aliases & Classifications for Nonalcoholic Fatty Liver Disease

MalaCards integrated aliases for Nonalcoholic Fatty Liver Disease:

Name: Nonalcoholic Fatty Liver Disease 12 26 38 15
Non-Alcoholic Fatty Liver Disease 12 26 17 74
Nonalcoholic Steatohepatitis 26 74
Fatty Liver 26 74
Steatosis 26 17
Susceptibility to Nonalcoholic Fatty Liver Disease 6
Non-Alcoholic Steatohepatitis 26
Non-Alcoholic Fatty Liver 17
Fatty Degeneration 74
Steatohepatitis 74
Nafld 26
Nash 26

Classifications:



Summaries for Nonalcoholic Fatty Liver Disease

Genetics Home Reference : 26 Non-alcoholic fatty liver disease (NAFLD) is a buildup of excessive fat in the liver that can lead to liver damage resembling the damage caused by alcohol abuse, but that occurs in people who do not drink heavily. The liver is a part of the digestive system that helps break down food, store energy, and remove waste products, including toxins. The liver normally contains some fat; an individual is considered to have a fatty liver (hepatic steatosis) if the liver contains more than 5 to 10 percent fat.

MalaCards based summary : Nonalcoholic Fatty Liver Disease, also known as non-alcoholic fatty liver disease, is related to hepatocellular carcinoma and psoriasis. An important gene associated with Nonalcoholic Fatty Liver Disease is MIR122 (MicroRNA 122), and among its related pathways/superpathways are Non-alcoholic fatty liver disease (NAFLD) and Glycerolipid metabolism. The drugs Tocopherol and Amlodipine have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney.

Disease Ontology : 12 A fatty liver disease characterized by the storing of excess fat in liver cells which is is not caused by heavy alcohol use.

Wikipedia : 77 Non-alcoholic fatty liver disease (NAFLD) is when excess fat builds up in the liver due to causes other... more...

Related Diseases for Nonalcoholic Fatty Liver Disease

Diseases in the Nonalcoholic Fatty Liver Disease family:

Fatty Liver Disease, Nonalcoholic 1 Fatty Liver Disease, Nonalcoholic 2

Diseases related to Nonalcoholic Fatty Liver Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 458)
# Related Disease Score Top Affiliating Genes
1 hepatocellular carcinoma 31.3 MIRLET7E MIRLET7D MIR34A MIR26A1 MIR203A MIR200A
2 psoriasis 31.2 MIRLET7E MIR203A MIR200A MIR122
3 breast cancer 30.5 MSR1 MIRLET7D MIR451A MIR429 MIR34A MIR203A
4 leukemia, acute lymphoblastic 30.4 MIRLET7E MIR451A MIR203A MIR130A
5 prostate cancer 30.3 MSR1 MIRLET7D MIR34A MIR203A MIR183 MIR10B
6 primary biliary cirrhosis 30.2 MIR451A MIR122
7 lymphoma, hodgkin, classic 29.9 MIR200A MIR140
8 muscular dystrophy, duchenne type 29.8 MIR34A MIR130A
9 lung cancer 29.1 MIRLET7E MIRLET7D MIR451A MIR429 MIR34A MIR26A1
10 fatty liver disease, nonalcoholic 2 12.4
11 fatty liver disease 12.3
12 long-chain 3-hydroxyacyl-coa dehydrogenase deficiency 12.2
13 lipoatrophy with diabetes, leukomelanodermic papules, liver steatosis, and hypertrophic cardiomyopathy 12.1
14 lipoatrophy with diabetes, hepatic steatosis, cardiomyopathy, and leukomelanodermic papules 12.1
15 fatty liver disease, nonalcoholic 1 11.9
16 liver disease 11.7
17 reye syndrome 11.6
18 choline deficiency disease 11.3
19 congenital generalized lipodystrophy 11.3
20 visceral steatosis, congenital 11.2
21 corticosteroid-binding globulin deficiency 11.1
22 lipodystrophy, congenital generalized, type 2 11.1
23 lipodystrophy, congenital generalized, type 3 11.1
24 lipodystrophy, familial partial, type 6 11.1
25 diabetes mellitus, noninsulin-dependent 11.0
26 nonalcoholic steatohepatitis 11.0
27 neutral lipid storage disease with myopathy 11.0
28 combined oxidative phosphorylation deficiency 16 11.0
29 morbid obesity and spermatogenic failure 11.0
30 mitochondrial dna depletion syndrome 4a 10.9
31 chylomicron retention disease 10.9
32 adrenomyodystrophy 10.9
33 lipodystrophy, congenital generalized, type 1 10.9
34 3-methylglutaconic aciduria, type v 10.9
35 hypermanganesemia with dystonia 1 10.9
36 lipodystrophy, congenital generalized, type 4 10.9
37 lipodystrophy, familial partial, type 5 10.9
38 muscular dystrophy, limb-girdle, autosomal recessive 18 10.9
39 interstitial lung and liver disease 10.9
40 combined oxidative phosphorylation deficiency 21 10.9
41 infantile liver failure syndrome 2 10.9
42 mitochondrial dna depletion syndrome 15 10.9
43 bile acid synthesis defect, congenital, 6 10.9
44 fibrosis, neurodegeneration, and cerebral angiomatosis 10.9
45 diabetes mellitus 10.8
46 hepatitis 10.8
47 polycystic ovary syndrome 10.6
48 sleep apnea 10.6
49 hepatitis b 10.6
50 lipid metabolism disorder 10.6

Graphical network of the top 20 diseases related to Nonalcoholic Fatty Liver Disease:



Diseases related to Nonalcoholic Fatty Liver Disease

Symptoms & Phenotypes for Nonalcoholic Fatty Liver Disease

Drugs & Therapeutics for Nonalcoholic Fatty Liver Disease

Drugs for Nonalcoholic Fatty Liver Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 371)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tocopherol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1406-66-2 14986
2
Amlodipine Approved Phase 4 88150-42-9 2162
3
Telmisartan Approved, Investigational Phase 4,Phase 1 144701-48-4 65999
4
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2 68521-88-0, 11128-99-7, 4474-91-3 172198 65143
5
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
6
Zinc Approved, Investigational Phase 4,Phase 2,Not Applicable 7440-66-6 32051
7
Insulin glargine Approved Phase 4,Phase 2 160337-95-1
8
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3 141758-74-9 15991534
9
Atorvastatin Approved Phase 4,Phase 3,Phase 2,Not Applicable 134523-00-5 60823
10
Ezetimibe Approved Phase 4,Phase 2 163222-33-1 150311
11
Liraglutide Approved Phase 4,Phase 3,Phase 2 204656-20-2 44147092
12
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 657-24-9 14219 4091
13
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 111025-46-8 4829
14
Iron Approved, Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7439-89-6, 15438-31-0 23925 27284
15
Rosiglitazone Approved, Investigational Phase 4,Phase 2,Not Applicable 122320-73-4 77999
16
Glucagon Approved Phase 4,Phase 2,Not Applicable 16941-32-5
17
tannic acid Approved Phase 4,Phase 3,Not Applicable 1401-55-4
18
Benzocaine Approved, Investigational Phase 4,Phase 3,Not Applicable 94-09-7, 1994-09-7 2337
19
Empagliflozin Approved Phase 4,Phase 2,Not Applicable 864070-44-0
20
Insulin Aspart Approved Phase 4 116094-23-6 16132418
21
Insulin Detemir Approved Phase 4 169148-63-4 5311023
22
Gliclazide Approved Phase 4 21187-98-4 3475
23
Glimepiride Approved Phase 4 93479-97-1 3476
24
Ethanol Approved Phase 4,Phase 3,Phase 2,Not Applicable 64-17-5 702
25
Rifampicin Approved Phase 4,Phase 1 13292-46-1 5381226 5458213
26
Saxagliptin Approved Phase 4 361442-04-8 11243969
27
Testosterone Approved, Experimental, Investigational Phase 4,Phase 2 58-22-0, 481-30-1 6013 10204
28
Testosterone enanthate Approved Phase 4,Phase 2 315-37-7 9416
29
Methyltestosterone Approved Phase 4,Phase 2 58-18-4 6010
30
Testosterone undecanoate Approved, Investigational Phase 4,Phase 2 5949-44-0
31
Rifaximin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 80621-81-4 6436173 46783403
32
Phentermine Approved, Illicit Phase 4 122-09-8 4771
33
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
34
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
35
Dulaglutide Approved, Investigational Phase 4,Not Applicable 923950-08-7
36
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59-02-9 14985
37
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 7440-70-2 271
38
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 1406-16-2
39
Ergocalciferol Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 50-14-6 5280793
40
Methionine Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 63-68-3 6137
41
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4,Phase 3 65-23-6 1054
42
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 59-30-3 6037
43
Vitamin D3 Approved, Nutraceutical Phase 4,Phase 3,Phase 2 67-97-0 5280795 6221
44
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 5283731 6433735
45
Ginseng Approved, Investigational, Nutraceutical Phase 4,Not Applicable 50647-08-0
46 Tocotrienol Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 6829-55-6
47
2,4-thiazolidinedione Investigational Phase 4,Phase 2 2295-31-0
48 Ipragliflozin Investigational Phase 4 761423-87-4
49
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
50 Tocopherols Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 726)
# Name Status NCT ID Phase Drugs
1 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
2 Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
3 The Effect Of Dual Treatment With L-Carnitine And Magnesium On Fatty Liver Unknown status NCT01956825 Phase 4
4 Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes Unknown status NCT02303730 Phase 4 Exenatide;insulin glargine
5 Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
6 Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
7 Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
8 Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients Unknown status NCT02210715 Phase 4 Isentress.
9 Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
10 Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects Completed NCT02147925 Phase 4 Liraglutide combined with metformin;Insulin glargine combined with metformin;Sitagliptin combined with metformin
11 Efficacy of Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets on the Patients With Newly Diagnosed Type 2 Diabetes Mellitus Combined With Non-alcoholic Fatty Liver Disease Active, not recruiting NCT03796975 Phase 4 Combination of Pioglitazone and Metformin Tablets;Metformin Hydrochloride Tablets
12 Comparison of The Effects of Thiazolidinediones(TZD), Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients With Fatty Liver Not yet recruiting NCT03646292 Phase 4 Pioglitazone;Empagliflozin;Combination of pioglitazone and empagliflozin
13 The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease Active, not recruiting NCT03222206 Phase 4 Salsalate
14 A Randomized, Prospective, Open Label, Active Control, Phase IV Study to Evaluate the Effects of Statin Monotherapy or Statin / Ezetimibe Combination Therapy on Hepatic Steatosis in Patients With Hyperlipidemia and Nonalcoholic Fatty Liver Disease Recruiting NCT03434613 Phase 4 Rosuvastatin;Rosuvastatin/ezetimibe combination
15 Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease Completed NCT01006889 Phase 4 Exenatide
16 Evaluation of the DPP-4 Inhibitor Sitagliptin in the Treatment of Non-Alcoholic Fatty Liver Disease Using MRI Withdrawn NCT02263677 Phase 4 Sitagliptin
17 Metformin for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) Terminated NCT00736385 Phase 4 Glucophage (Metformin);Placebo
18 University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial) Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
19 Silymarin in NAFLD Not yet recruiting NCT02973295 Phase 4 Silymarin
20 Antidiabetic Effects on Intrahepatic Fat Completed NCT03068065 Phase 4 Liraglutide;Metformin;Gliclazide
21 Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment Completed NCT01002547 Phase 4 pioglitazone-placebo;pioglitazone;pioglitazone-placebo;Vitamin E-placebo
22 SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD Recruiting NCT02649465 Phase 4 Tofogliflozin;Glimepiride
23 Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone Completed NCT02875821 Phase 4 Ipragliflozin;metformin with pioglitazone
24 Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver Not yet recruiting NCT03604016 Phase 4 Besifovir dipivoxil;L-carnitine;Tenofovir Alafenamide
25 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis Recruiting NCT02051842 Phase 4 Metadoxine
26 Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4 Exenatide
27 A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD Completed NCT02285205 Phase 4 Oral administration of Lobeglitazone
28 Natural Soybean-derived Femarelle ®for Patients With Non Alcoholic Fatty Liver Disease Withdrawn NCT01269320 Phase 4 Femarelle
29 The Effect of Vitamin D Supplementation in Type 2 Diabetes Completed NCT01854463 Phase 4 Vitamin D3;placebo
30 The Effects of PXR Activation on Hepatic Fat Content Completed NCT02329405 Phase 4 Rifampicin;Placebo
31 Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS) Recruiting NCT02500147 Phase 4 Metformin;Placebo
32 Impact of Short-term Fructose-enriched Diet on Serum Metabolome by Normal- and Over-weighed Women. Completed NCT03444233 Phase 4
33 Fatty Liver Study in Patients With Type II Diabetes Terminated NCT02365233 Phase 4 DPP4 inhibitor;Pioglitazone;Lantus insulin
34 Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes Completed NCT02637973 Phase 4 Empagliflozin;Placebo
35 Study on Effects of Testosterone Replacement Therapy in Hypogonadal Type 2 Diabetic Patients" (SETH2) Completed NCT03792321 Phase 4 Testosterone Undecanoate;Placebo
36 Rifaximin in Fatty Liver Disease Terminated NCT01355575 Phase 4 Rifaximin
37 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Recruiting NCT02964715 Phase 4 Empagliflozin
38 Efficacy and Safety of Berberine in Non-alcoholic Steatohepatitis Recruiting NCT03198572 Phase 4 Placebo;Berberine
39 Pioglitazone in Hepatitis C Completed NCT00189163 Phase 4 Pioglitazone;Placebo Oral Tablet
40 Effectiveness and Tolerability of Phentermine in Patients Under Bariatric Surgery Recruiting NCT03849729 Phase 4 Phentermine
41 Effects of Testosterone Undecanoate vs Placebo on Intrahepatic Fat Content in Obese Men With T2DM and Hypogonadism Not yet recruiting NCT03851627 Phase 4 Testosterone Undecanoate;Placebo
42 Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes Completed NCT00998335 Phase 4 Long-acting bedtime insulin detemir (Levemir);Insulin detemir and pre-meal insulin aspart.
43 Weight Loss Improves Renal Hemodynamics Completed NCT01356394 Phase 4
44 The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalassemia Major Recruiting NCT02984475 Phase 4 Metformin
45 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4 Pioglitazone;Placebo
46 Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis Completed NCT02331589 Phase 4 KRG (Korea Red ginseng);Placebo (for KRG)
47 Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis Completed NCT01650181 Phase 4 Metformin;Metformin
48 Effects of Rosiglitazone and Alpha-lipoic Acid on the Patients With Pathologically Proved NASH Terminated NCT01406704 Phase 4 Rosiglitazone;alpha-lipoic acid;Rosiglitazone/alpha-lipoic acid
49 Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00160407 Phase 4 Orlistat (Xenical)
50 Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST) Not yet recruiting NCT03648554 Phase 4 dulaglutide (TRULICITY®) 1.5 mg

Search NIH Clinical Center for Nonalcoholic Fatty Liver Disease

Genetic Tests for Nonalcoholic Fatty Liver Disease

Anatomical Context for Nonalcoholic Fatty Liver Disease

MalaCards organs/tissues related to Nonalcoholic Fatty Liver Disease:

42
Liver, Testes, Kidney, Endothelial, Heart, Ovary, Bone

Publications for Nonalcoholic Fatty Liver Disease

Articles related to Nonalcoholic Fatty Liver Disease:

(show top 50) (show all 6380)
# Title Authors Year
1
Nonalcoholic Fatty Liver Disease Aggravated the Severity of Acute Pancreatitis in Patients. ( 30805370 )
2019
2
Association of TM6SF2 rs58542926 gene polymorphism with the risk of non-alcoholic fatty liver disease and colorectal adenoma in Chinese Han population. ( 30727943 )
2019
3
Liver fibrosis is associated with risk for colorectal adenoma in patients with nonalcoholic fatty liver disease. ( 30732129 )
2019
4
The association between nonalcoholic fatty liver disease and risk of colorectal adenoma and cancer incident and recurrence: a meta-analysis of observational studies. ( 30791768 )
2019
5
Association between non-alcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: an updated meta-analysis. ( 30657626 )
2019
6
Interatrial septal fat thickness and left atrial stiffness are mechanistic links between nonalcoholic fatty liver disease and incident atrial fibrillation. ( 30548700 )
2019
7
18F-FDG PET/CT AS AN ASSESSMENT TOOL OF HEPATOCELLULAR CARCINOMA SECONDARY TO NON-ALCOHOLIC FATTY LIVER DISEASE DEVELOPMENT IN EXPERIMENTAL MODEL. ( 30892403 )
2019
8
Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. ( 30842500 )
2019
9
Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease. ( 30791782 )
2019
10
Clinical features of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without advanced fibrosis. ( 30668889 )
2019
11
Among Medicare Patients With Hepatocellular Carcinoma, Non-alcoholic Fatty Liver Disease is the Most Common Etiology and Cause of Mortality. ( 30672817 )
2019
12
Liver Resection for Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: a Multicenter Propensity Matching Analysis with HBV-HCC. ( 30617773 )
2019
13
Diabetic Retinopathy as a Risk Factor Associated with the Development of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. ( 30625487 )
2019
14
Role of MicroRNAs in the Development of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. ( 30312023 )
2019
15
Nonalcoholic fatty liver disease is associated with breast cancer in nonobese women. ( 30686716 )
2019
16
Aromatase Inhibitors and Newly Developed Nonalcoholic Fatty Liver Disease in Postmenopausal Patients with Early Breast Cancer: A Propensity Score-Matched Cohort Study. ( 30679317 )
2019
17
Crohn's Disease is Associated with an Increased Prevalence of Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study using Magnetic Resonance Proton Density Fat Fraction Mapping. ( 30876963 )
2019
18
Renal Dysfunction in Patients With Nonalcoholic Fatty Liver Disease is Related to the Presence of Diabetes Mellitus and Severity of Liver Disease. ( 30765935 )
2019
19
SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review. ( 30788048 )
2019
20
Letter to Editor: Role of Pharmacotherapy in Patients With Coexisting Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. ( 30734333 )
2019
21
Non-alcoholic fatty liver disease is associated with low-grade albuminuria in men without diabetes mellitus. ( 30745809 )
2019
22
Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study. ( 30682184 )
2019
23
The utility of ezetimibe therapy in nonalcoholic fatty liver disease. ( 30840809 )
2019
24
Systems Genetics of Hepatic Metabolome Reveals Octopamine as a Target for Non-Alcoholic Fatty Liver Disease Treatment. ( 30842494 )
2019
25
Current treatment options for nonalcoholic fatty liver disease. ( 30844893 )
2019
26
Vitamin D status and non-alcoholic fatty liver disease in patients with type 1 diabetes. ( 30847862 )
2019
27
Nonalcoholic fatty liver disease alters microcystin-LR toxicokinetics and acute toxicity. ( 30849452 )
2019
28
Short sleep duration is a risk of incident nonalcoholic fatty liver disease: a population-based longitudinal study. ( 30851175 )
2019
29
Evaluating the association of serum ferritin and hepatic iron with disease severity in non-alcoholic fatty liver disease. ( 30851216 )
2019
30
Protective effect and mechanism of Qiwei Tiexie capsule on 3T3-L1 adipocytes cells and rats with nonalcoholic fatty liver disease by regulating LXRα, PPARγ, and NF-κB-iNOS-NO signaling pathways. ( 30851372 )
2019
31
TRIB1 rs17321515 and rs2954029 gene polymorphisms increase the risk of non-alcoholic fatty liver disease in Chinese Han population. ( 30851741 )
2019
32
Clinical effect of the extract of TCM Fructus akebiae combined with ursodeoxycholic acid on nonalcoholic fatty liver disease. ( 30852481 )
2019
33
Combined Amelioration of Ginsenoside (Rg1, Rb1, and Rg3)-enriched Korean Red Ginseng and Probiotic Lactobacillus on Non-Alcoholic Fatty Liver Disease. ( 30854954 )
2019
34
Ferulic acid ameliorates nonalcoholic fatty liver disease and modulates the gut microbiota composition in high-fat diet fed ApoE-/- mice. ( 30856537 )
2019
35
Transgenerational Impact Of Maternal Obesogenic Diet On Offspring Bile Acid Homeostasis And Non-Alcoholic Fatty Liver Disease. ( 30860882 )
2019
36
Inhibition of microRNA-124a attenuates nonalcoholic fatty liver disease via upregulation of adipose triglyceride lipase and the effect of liraglutide intervention. ( 30861258 )
2019
37
Mitigative effects of the bioactive flavonol fisetin on high-fat/high-sucrose induced nonalcoholic fatty liver disease in rats. ( 30861601 )
2019
38
Nutritional Intake and the Risk for Non-Alcoholic Fatty Liver Disease (NAFLD). ( 30862016 )
2019
39
Metabolomics Characterizes the Effects and Mechanisms of Quercetin in Nonalcoholic Fatty Liver Disease Development. ( 30862046 )
2019
40
Comorbidities and Nonalcoholic Fatty Liver Disease: The Chicken, the Egg, or Both? ( 30867626 )
2019
41
Population Management of Nonalcoholic Fatty Liver Disease. ( 30867627 )
2019
42
Berberine attenuates hepatic oxidative stress in rats with non-alcoholic fatty liver disease via the Nrf2/ARE signalling pathway. ( 30867696 )
2019
43
Comparison of laboratory indices of non-alcoholic fatty liver disease for the detection of incipient kidney dysfunction. ( 30867987 )
2019
44
Berberine Ameliorates High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Rats via Activation of SIRT3/AMPK/ACC Pathway. ( 30868489 )
2019
45
Letter: nonalcoholic fatty liver disease is associated with a history of osteoporotic fractures but not with low bone mineral density. ( 30868628 )
2019
46
Letter: non-alcoholic fatty liver disease is associated with a history of osteoporotic fractures but not with low bone mineral density-authors' reply. ( 30868629 )
2019
47
Association Of Non-Alcoholic Fatty Liver Disease With Serum Uric Acid. ( 30868786 )
2019
48
Fecal and blood microbiota profiles and presence of nonalcoholic fatty liver disease in obese versus lean subjects. ( 30870486 )
2019
49
Circulating Iron Levels Interaction with Central Obesity on the Risk of Nonalcoholic Fatty Liver Disease: A Case-Control Study in Southeast China. ( 30870854 )
2019
50
Nonalcoholic fatty liver disease and the gut microbiome: Are bacteria responsible for fatty liver? ( 30871368 )
2019

Variations for Nonalcoholic Fatty Liver Disease

ClinVar genetic disease variations for Nonalcoholic Fatty Liver Disease:

6 (show top 50) (show all 92)
# Gene Variation Type Significance SNP ID Assembly Location
1 PNPLA3 NM_025225.2(PNPLA3): c.-112A> T single nucleotide variant Likely benign rs531789428 GRCh38 Chromosome 22, 43923800: 43923800
2 PNPLA3 NM_025225.2(PNPLA3): c.-112A> T single nucleotide variant Likely benign rs531789428 GRCh37 Chromosome 22, 44319680: 44319680
3 PNPLA3 NM_025225.2(PNPLA3): c.-111G> A single nucleotide variant Likely benign rs548897706 GRCh38 Chromosome 22, 43923801: 43923801
4 PNPLA3 NM_025225.2(PNPLA3): c.-111G> A single nucleotide variant Likely benign rs548897706 GRCh37 Chromosome 22, 44319681: 44319681
5 PNPLA3 NM_025225.2(PNPLA3): c.-44C> G single nucleotide variant Uncertain significance rs773713393 GRCh38 Chromosome 22, 43923868: 43923868
6 PNPLA3 NM_025225.2(PNPLA3): c.-44C> G single nucleotide variant Uncertain significance rs773713393 GRCh37 Chromosome 22, 44319748: 44319748
7 PNPLA3 NM_025225.2(PNPLA3): c.972C> T (p.Leu324=) single nucleotide variant Likely benign rs116679026 GRCh37 Chromosome 22, 44333145: 44333145
8 PNPLA3 NM_025225.2(PNPLA3): c.972C> T (p.Leu324=) single nucleotide variant Likely benign rs116679026 GRCh38 Chromosome 22, 43937265: 43937265
9 PNPLA3 NM_025225.2(PNPLA3): c.980-15A> C single nucleotide variant Likely benign rs144872932 GRCh37 Chromosome 22, 44335858: 44335858
10 PNPLA3 NM_025225.2(PNPLA3): c.980-15A> C single nucleotide variant Likely benign rs144872932 GRCh38 Chromosome 22, 43939978: 43939978
11 PNPLA3 NM_025225.2(PNPLA3): c.992A> G (p.Glu331Gly) single nucleotide variant Likely benign rs144233415 GRCh37 Chromosome 22, 44335885: 44335885
12 PNPLA3 NM_025225.2(PNPLA3): c.992A> G (p.Glu331Gly) single nucleotide variant Likely benign rs144233415 GRCh38 Chromosome 22, 43940005: 43940005
13 PNPLA3 NM_025225.2(PNPLA3): c.1209C> T (p.Pro403=) single nucleotide variant Uncertain significance rs184910573 GRCh37 Chromosome 22, 44340667: 44340667
14 PNPLA3 NM_025225.2(PNPLA3): c.1209C> T (p.Pro403=) single nucleotide variant Uncertain significance rs184910573 GRCh38 Chromosome 22, 43944787: 43944787
15 PNPLA3 NM_025225.2(PNPLA3): c.1340G> A (p.Arg447Gln) single nucleotide variant Uncertain significance rs147289545 GRCh37 Chromosome 22, 44342156: 44342156
16 PNPLA3 NM_025225.2(PNPLA3): c.1340G> A (p.Arg447Gln) single nucleotide variant Uncertain significance rs147289545 GRCh38 Chromosome 22, 43946276: 43946276
17 PNPLA3 NM_025225.2(PNPLA3): c.1358G> T (p.Ser453Ile) single nucleotide variant Likely benign rs6006460 GRCh37 Chromosome 22, 44342174: 44342174
18 PNPLA3 NM_025225.2(PNPLA3): c.1358G> T (p.Ser453Ile) single nucleotide variant Likely benign rs6006460 GRCh38 Chromosome 22, 43946294: 43946294
19 PNPLA3 NM_025225.2(PNPLA3): c.*19T> G single nucleotide variant Uncertain significance rs569255289 GRCh37 Chromosome 22, 44342281: 44342281
20 PNPLA3 NM_025225.2(PNPLA3): c.*19T> G single nucleotide variant Uncertain significance rs569255289 GRCh38 Chromosome 22, 43946401: 43946401
21 PNPLA3 NM_025225.2(PNPLA3): c.*71T> G single nucleotide variant Uncertain significance rs886057601 GRCh37 Chromosome 22, 44342333: 44342333
22 PNPLA3 NM_025225.2(PNPLA3): c.*71T> G single nucleotide variant Uncertain significance rs886057601 GRCh38 Chromosome 22, 43946453: 43946453
23 PNPLA3 NM_025225.2(PNPLA3): c.*691_*692dupAA duplication Likely benign rs397716964 GRCh37 Chromosome 22, 44342953: 44342954
24 PNPLA3 NM_025225.2(PNPLA3): c.*691_*692dupAA duplication Likely benign rs397716964 GRCh38 Chromosome 22, 43947073: 43947074
25 PNPLA3 NM_025225.2(PNPLA3): c.*889A> G single nucleotide variant Likely benign rs1810508 GRCh38 Chromosome 22, 43947271: 43947271
26 PNPLA3 NM_025225.2(PNPLA3): c.*889A> G single nucleotide variant Likely benign rs1810508 GRCh37 Chromosome 22, 44343151: 44343151
27 PNPLA3 NM_025225.2(PNPLA3): c.*988_*989dupAA duplication Likely benign rs3083314 GRCh38 Chromosome 22, 43947370: 43947371
28 PNPLA3 NM_025225.2(PNPLA3): c.*988_*989dupAA duplication Likely benign rs3083314 GRCh37 Chromosome 22, 44343250: 44343251
29 PNPLA3 NM_025225.2(PNPLA3): c.*1090A> G single nucleotide variant Likely benign rs9626058 GRCh38 Chromosome 22, 43947472: 43947472
30 PNPLA3 NM_025225.2(PNPLA3): c.*1090A> G single nucleotide variant Likely benign rs9626058 GRCh37 Chromosome 22, 44343352: 44343352
31 PNPLA3 NM_025225.2(PNPLA3): c.*987_*989dupAAA duplication Uncertain significance rs3083314 GRCh38 Chromosome 22, 43947369: 43947371
32 PNPLA3 NM_025225.2(PNPLA3): c.-168C> A single nucleotide variant Likely benign rs140746182 GRCh38 Chromosome 22, 43923744: 43923744
33 PNPLA3 NM_025225.2(PNPLA3): c.-168C> A single nucleotide variant Likely benign rs140746182 GRCh37 Chromosome 22, 44319624: 44319624
34 PNPLA3 NM_025225.2(PNPLA3): c.187+12G> A single nucleotide variant Likely benign rs116795637 GRCh38 Chromosome 22, 43924110: 43924110
35 PNPLA3 NM_025225.2(PNPLA3): c.187+12G> A single nucleotide variant Likely benign rs116795637 GRCh37 Chromosome 22, 44319990: 44319990
36 PNPLA3 NM_025225.2(PNPLA3): c.216T> C (p.Leu72=) single nucleotide variant Uncertain significance rs147412464 GRCh38 Chromosome 22, 43926963: 43926963
37 PNPLA3 NM_025225.2(PNPLA3): c.216T> C (p.Leu72=) single nucleotide variant Uncertain significance rs147412464 GRCh37 Chromosome 22, 44322843: 44322843
38 PNPLA3 NM_025225.2(PNPLA3): c.309G> A (p.Pro103=) single nucleotide variant Likely benign rs79118505 GRCh38 Chromosome 22, 43927056: 43927056
39 PNPLA3 NM_025225.2(PNPLA3): c.309G> A (p.Pro103=) single nucleotide variant Likely benign rs79118505 GRCh37 Chromosome 22, 44322936: 44322936
40 PNPLA3 NM_025225.2(PNPLA3): c.646A> C (p.Thr216Pro) single nucleotide variant Uncertain significance rs35726887 GRCh37 Chromosome 22, 44328917: 44328917
41 PNPLA3 NM_025225.2(PNPLA3): c.646A> C (p.Thr216Pro) single nucleotide variant Uncertain significance rs35726887 GRCh38 Chromosome 22, 43933037: 43933037
42 PNPLA3 NM_025225.2(PNPLA3): c.659A> G (p.Tyr220Cys) single nucleotide variant Uncertain significance rs143392071 GRCh37 Chromosome 22, 44328930: 44328930
43 PNPLA3 NM_025225.2(PNPLA3): c.659A> G (p.Tyr220Cys) single nucleotide variant Uncertain significance rs143392071 GRCh38 Chromosome 22, 43933050: 43933050
44 PNPLA3 NM_025225.2(PNPLA3): c.980-14A> C single nucleotide variant Uncertain significance rs781212740 GRCh37 Chromosome 22, 44335859: 44335859
45 PNPLA3 NM_025225.2(PNPLA3): c.980-14A> C single nucleotide variant Uncertain significance rs781212740 GRCh38 Chromosome 22, 43939979: 43939979
46 PNPLA3 NM_025225.2(PNPLA3): c.1112+14G> A single nucleotide variant Uncertain significance rs138736228 GRCh37 Chromosome 22, 44336019: 44336019
47 PNPLA3 NM_025225.2(PNPLA3): c.1112+14G> A single nucleotide variant Uncertain significance rs138736228 GRCh38 Chromosome 22, 43940139: 43940139
48 PNPLA3 NM_025225.2(PNPLA3): c.1300A> G (p.Lys434Glu) single nucleotide variant Likely benign rs2294918 GRCh37 Chromosome 22, 44342116: 44342116
49 PNPLA3 NM_025225.2(PNPLA3): c.1300A> G (p.Lys434Glu) single nucleotide variant Likely benign rs2294918 GRCh38 Chromosome 22, 43946236: 43946236
50 PNPLA3 NM_025225.2(PNPLA3): c.1419C> T (p.Pro473=) single nucleotide variant Uncertain significance rs376208148 GRCh37 Chromosome 22, 44342235: 44342235

Expression for Nonalcoholic Fatty Liver Disease

Search GEO for disease gene expression data for Nonalcoholic Fatty Liver Disease.

Pathways for Nonalcoholic Fatty Liver Disease

Pathways related to Nonalcoholic Fatty Liver Disease according to KEGG:

38
# Name Kegg Source Accession
1 Non-alcoholic fatty liver disease (NAFLD) hsa04932
2 Glycerolipid metabolism hsa00561

Pathways related to Nonalcoholic Fatty Liver Disease according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.8 MIR10B MIR122 MIR183 MIR200A MIR203A MIR26A1
2 10.96 MIR203A MIRLET7D
3 10.79 MIR200A MIR429
4 10.4 MIRLET7D MIRLET7E

GO Terms for Nonalcoholic Fatty Liver Disease

Cellular components related to Nonalcoholic Fatty Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.65 MIR10B MIR122 MIR130A MIR140 MIR183 MIR26A1
2 micro-ribonucleoprotein complex GO:0035068 9.44 MIR10B MIR122 MIR130A MIR140 MIR183 MIR200A

Biological processes related to Nonalcoholic Fatty Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 gene silencing by miRNA GO:0035195 9.47 MIR10B MIR122 MIR130A MIR140 MIR183 MIR200A
2 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.32 MIR130A MIR26A1
3 negative regulation of vascular smooth muscle cell proliferation GO:1904706 9.26 MIR140 MIR34A
4 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.16 MIR26A1 MIR451A
5 negative regulation of vascular associated smooth muscle cell migration GO:1904753 8.96 MIR140 MIR34A

Molecular functions related to Nonalcoholic Fatty Liver Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.32 MIR10B MIR130A MIR140 MIR200A MIR203A MIR26A1
2 RNA polymerase II complex binding GO:0000993 8.96 MIR140 MIR378A

Sources for Nonalcoholic Fatty Liver Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....